The clinical biostatistics team has strong connection with the Biometry department (Head A. Savignoni), the early phase clinical trial and precision medicine unit where patients are treated with drugs in development (Head C. Le Tourneau), the translational research department in particular
the Circulating Tumor Biomarkers laboratory (Charlotte Proudhon), and of course the other teams of the U900.
Not exact matches
Unfortunately, the high background of normal proteins, along with the presence of
circulating phosphatases and other degradation enzymes, consistently stump researchers searching for these rare
tumor biomarkers.
Researchers have long dreamed of developing simple blood tests to monitor and diagnose solid
tumors, but the scarcity of
circulating cancer
biomarkers has held the field back.
«Despite the identification of
circulating tumor cells (CTCs) and cell - free DNA (cfDNA) as
biomarkers capable of providing clinically relevant information in cancer patients, at present their identification is not routinely used in clinical practice,» explains Silvia Morbelli, MD, PhD, of the IRCCS San Martino — IST National Cancer Research Institute and University of Genoa in Genoa, Italy.
Berkeley researchers isolated
circulating tumor cells from the blood of breast cancer patients, then used microscale physics to design a precision test for protein
biomarkers, which are indicators of cancer.
Circulating cell - free DNA (cfDNA) isolated from plasma or serum by noninvasive procedures can serve as a «liquid biopsy» and has potential as a
biomarker for the
tumor burden and survival prediction of breast cancer (BC).
Research Paper A dual
biomarker detection platform for quantitating
circulating tumor DNA (ctDNA) Chunyan Cai, Zhenzhong Guo, Yiping Cao, Weiying Zhang, Yong Chen Nanotheranostics 2018; 2 (1): 12 - 20.
Blood
Biomarkers Identified in Drug - Resistant Cancer
Tumor Cells November 2016 While searching for a non-invasive way to detect prostate cancer cells
circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with...
Uncovers
biomarkers and uses
circulating tumor cells and
circulating tumor - free DNA to predict responses to treatment